Full Text Journal Articles from
Abstract 31188728

Advertisement

Find full text journal articles








Prostate Transition Zone Fibrosis is Associated with Clinical Progression in the MTOPS Study.

PMID: 31188728 (view PubMed database entry)
DOI: 10.1097/ju.0000000000000385 (read at publisher's website )
PMCID: PMC7339116 (free full text version available)

Download PDF Download PDF

Jill A Macoska, Kristen S Uchtmann, Glen E Leverson, Kevin T McVary, William A Ricke,

PURPOSE:Medications targeting androgen receptor activity (eg finasteride) or smooth muscle contractility (eg doxazosin) do not resolve lower urinary tract symptoms indicative of lower urinary tract dysfunction in an important subgroup of men. Recently fibrosis has been implicated as another pathobiology contributing to male lower urinary tract symptoms but to our knowledge no systematic studies have been done to assess fibrosis in the context of medical treatment. We determine whether fibrotic changes in the prostate transition zone are associated with an increased risk of clinical progression in participants treated with doxazosin, finasteride or finasteride plus doxazosin in the MTOPS (Medical Therapy of Prostatic Symptoms) study. MATERIALS AND METHODS:Transition zone biopsy tissues from men who did or did not experience clinical progression on placebo, doxazosin, finasteride or combination therapy were assessed for collagen content and architectural changes using picrosirius red birefringence and CT-FIRE (Curvelet Transform-Fiber Extraction) analysis. Correlations were made with annotated demographic and clinical data. Statistical analyses were done with the Pearson correlation coefficient, ANOVA and the t-test. RESULTS:High levels of wavy, aligned prostate transition zone collagen significantly correlated with an increased risk of clinical progression among MTOPS trial participants treated with doxazosin plus finasteride, particularly those with a high body mass index. CONCLUSIONS:Fibrotic changes in the prostate transition zone are associated with an increased risk of clinical progression in men treated with doxazosin plus finasteride. Antifibrotic therapeutics might provide a new treatment approach in men with lower urinary tract dysfunction who do not respond to current medical treatment approaches.

J Urol (The Journal of urology)
[2019, 202(6):1240-1247]

Cited: 1 time

AltMetric Statistics

Additional resources:




Advertisement

Disclaimer
0.6158 s